Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 9/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.39 |
| ▸ | CSK | P41240 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25166249 | 1.00 | EHMT2 (0.50) | EHMT2EHMT1SRCKDRCSK | |
| SCHEMBL30329803 | 0.87 | EHMT2 (0.67) | EHMT2EHMT1SRCKDRCSK | |
| SCHEMBL25165926 | 0.87 | EHMT2 (0.67) | EHMT2EHMT1SRCKDRCSK | |
| SCHEMBL25166694 | 0.86 | EPHB4 (0.35) | EHMT2EHMT1EPHB4KCNH2 | |
| SCHEMBL30330226 | 0.86 | EPHB4 (0.35) | EHMT2EHMT1EPHB4KCNH2 | |
| SCHEMBL25165871 | 0.80 | EHMT2 (0.67) | EHMT2EHMT1SRCIGF1R | |
| SCHEMBL30329669 | 0.80 | EHMT2 (0.67) | EHMT2EHMT1SRCIGF1R | |
| SCHEMBL19476604 | 0.75 | EHMT2 (0.63) | EHMT2EHMT1SRCDNMT1IGF1R | |
| SCHEMBL19476600 | 0.75 | EHMT2 (0.58) | EHMT2EHMT1SRCDNMT1IGF1R | |
| SCHEMBL30367491 | 0.75 | EHMT2 (0.63) | EHMT2EHMT1SRCDNMT1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | EHMT2 2/4885EHMT1 1/4885SRC 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.